Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Zhi‐Nan Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5512-4623; OpenAlex author ID A5027880821, A5108417556. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. NDUFS1-Mediated Mitochondrial Complex I Activity Maintains Pancreatic Cancer Stemness by Promoting PAX2 Hypomethylation. Co-author DOI 10.1002/mco2.70678↗
  2. METTL3/IGF2BP3 mediates ORC6 via N6-methyladenosine modification to promote the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gene.2025.149468↗
  3. Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis. First author DOI 10.18632/aging.206043↗
  4. A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2022.1015042↗
  5. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2020.05.005↗
  6. Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells. Last author PMID 31312365↗
  7. RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion. Co-author DOI 10.1038/cddis.2017.230↗
  8. Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection. Co-author PMID 26885196↗
  9. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Co-author DOI 10.1158/1078-0432.ccr-13-0621↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin‐Yu Fan · 2 shared papers, 2022–2026 · strength 0.39
  2. Jing Ma · 1 shared paper, 2024 · strength 0.36
  3. Limin Hou · 1 shared paper, 2024 · strength 0.36
  4. Ling Li · 1 shared paper, 2026 · strength 0.24
  5. Zhiyong Yang · 1 shared paper, 2025 · strength 0.23
  6. Wenjing Song · 1 shared paper, 2025 · strength 0.23
  7. Yang Shi · 1 shared paper, 2025 · strength 0.23
  8. Jian‐Li Jiang · 2 shared papers, 2019–2020 · strength 0.21
  9. Ling Li · 2 shared papers, 2013–2022 · strength 0.18
  10. Xue Liang · 1 shared paper, 2022 · strength 0.15
  11. Hao Wang · 1 shared paper, 2022 · strength 0.15
  12. Liang Xu · 2 shared papers, 2013–2019 · strength 0.12
  13. Xiaoqing Wu · 2 shared papers, 2013–2019 · strength 0.12
  14. Yinghui Zhou · 1 shared paper, 2020 · strength 0.12
  15. Bin Wang · 1 shared paper, 2019 · strength 0.09
  16. Xinyu Fan · 1 shared paper, 2019 · strength 0.09
  17. Yanni Xu · 1 shared paper, 2017 · strength 0.06
  18. Liang Chu · 1 shared paper, 2017 · strength 0.06
  19. Zongsuo Liang · 1 shared paper, 2017 · strength 0.06
  20. Yao Meng · 1 shared paper, 2015 · strength 0.06
  21. Ling Li · 1 shared paper, 2015 · strength 0.06
  22. Theodore Steven Lawrence · 1 shared paper, 2013 · strength 0.03
  23. Jiayuh Lin · 1 shared paper, 2013 · strength 0.03
  24. David M. Karnak · 1 shared paper, 2013 · strength 0.03
  25. Diane M. Simeone · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.